Clinical Trial Update: Aromatase (CYP19) Polymorphism Between AI-responsive and AI-resistant Breast Cancer in Korea

View source ↗

Summary

A Korean clinical trial investigating CYP19 polymorphism and aromatase inhibitor response in breast cancer has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Aromatase inhibitors (aromatase inhibitor)

Snippet

Sponsor: Samsung Medical Center | Conditions: Polymorphism, CYP19 | Status: SUSPENDED